Colimycin
Colistimethate, Coly-mycin M (colimycin) is a protein pharmaceutical. Colimycin was first approved as Coly-mycin m on 1982-01-01.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
118 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pneumonia | D011014 | EFO_0003106 | J18 | 1 | 6 | 15 | 7 | 13 | 39 |
| Infections | D007239 | EFO_0000544 | — | 1 | 3 | 10 | 12 | 11 | 34 |
| Ventilator-associated pneumonia | D053717 | EFO_1001865 | J95.851 | — | 6 | 12 | 2 | 6 | 22 |
| Communicable diseases | D003141 | — | — | — | 1 | 8 | 8 | 5 | 21 |
| Sepsis | D018805 | EFO_0001420 | A41.9 | 1 | 2 | 5 | 4 | 3 | 13 |
| Bacteremia | D016470 | EFO_0003033 | R78.81 | 1 | 2 | 4 | 2 | 6 | 13 |
| Cystic fibrosis | D003550 | EFO_0000390 | E84 | 1 | 1 | 3 | 5 | 2 | 12 |
| Bacterial infections | D001424 | — | A49 | 1 | 1 | 2 | 7 | 2 | 12 |
| Fibrosis | D005355 | — | — | 1 | 1 | 2 | 4 | 1 | 9 |
| Critical illness | D016638 | — | — | 1 | 1 | 3 | 3 | 1 | 8 |
Show 18 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 1 | — | 3 | — | — | 4 |
| Bronchiectasis | D001987 | — | J47 | — | 1 | 2 | — | — | 3 |
| Iatrogenic disease | D007049 | — | — | — | 1 | 1 | — | — | 2 |
| Bronchitis | D001991 | — | J40 | — | — | 1 | — | 1 | 2 |
| Acute kidney injury | D058186 | — | N17 | — | — | 1 | — | 1 | 2 |
| Septic shock | D012772 | — | A48.3 | — | — | 1 | — | — | 1 |
| Neoplasms | D009369 | — | C80 | — | 1 | 1 | — | — | 1 |
| Covid-19 | D000086382 | — | U07.1 | — | — | 1 | — | — | 1 |
| Coinfection | D060085 | — | — | — | — | 1 | — | — | 1 |
| Esophageal neoplasms | D004938 | — | C15 | — | — | 1 | — | — | 1 |
Show 1 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pseudomonas infections | D011552 | EFO_0001076 | A41.52 | 1 | 1 | — | — | 1 | 3 |
| Pseudomonas aeruginosa | D011550 | NCBITaxon_287 | — | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Osteomyelitis | D010019 | EFO_0003102 | M86 | 1 | — | — | — | — | 1 |
| Pneumococcal infections | D011008 | EFO_0000772 | J13 | 1 | — | — | — | — | 1 |
| Disease resistance | D060467 | — | — | 1 | — | — | — | — | 1 |
| Gram-negative bacteria | D006090 | — | — | 1 | — | — | — | — | 1 |
| Brain diseases | D001927 | — | G93.40 | 1 | — | — | — | — | 1 |
| Hepatic encephalopathy | D006501 | — | K72.91 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Respiratory aspiration | D053120 | EFO_1001839 | — | — | — | — | — | 2 | 2 |
| Escherichia coli infections | D004927 | EFO_1001318 | B96.20 | — | — | — | — | 1 | 1 |
| Klebsiella pneumoniae | D007711 | NCBITaxon_573 | B96.1 | — | — | — | — | 1 | 1 |
| Neurotoxicity syndromes | D020258 | — | G92 | — | — | — | — | 1 | 1 |
| Renal insufficiency | D051437 | — | N19 | — | — | — | — | 1 | 1 |
| Disease | D004194 | EFO_0000408 | R69 | — | — | — | — | 1 | 1 |
| Toxemia | D014115 | — | — | — | — | — | — | 1 | 1 |
| Molecular diagnostic techniques | D025202 | — | — | — | — | — | — | 1 | 1 |
| Asymptomatic infections | D058345 | — | — | — | — | — | — | 1 | 1 |
| Microbial drug resistance | D004352 | — | — | — | — | — | — | 1 | 1 |
Show 2 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Colimycin |
| INN | colistimethate sodium |
| Description | Colistin, also known as polymyxin E, is an antibiotic medication used as a last-resort treatment for multidrug-resistant Gram-negative infections including pneumonia. These may involve bacteria such as Pseudomonas aeruginosa, Klebsiella pneumoniae, or Acinetobacter. It comes in two forms: colistimethate sodium can be injected into a vein, injected into a muscle, or inhaled, and colistin sulfate is mainly applied to the skin or taken by mouth. Colistimethate sodium is a prodrug; it is produced by the reaction of colistin with formaldehyde and sodium bisulfite, which leads to the addition of a sulfomethyl group to the primary amines of colistin. Colistimethate sodium is less toxic than colistin when administered parenterally. In aqueous solutions it undergoes hydrolysis to form a complex mixture of partially sulfomethylated derivatives, as well as colistin. Resistance to colistin began to appear as of 2015.
|
| Classification | Protein |
| Drug class | antibiotics (Streptomyces strain) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CCC(C)CCCCC(=O)NCC[C@@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H]([C@@H](C)O)NC1=O |
Identifiers
| PDB | — |
| CAS-ID | 1066-17-7 |
| RxCUI | — |
| ChEMBL ID | CHEMBL507048 |
| ChEBI ID | — |
| PubChem CID | 5311054 |
| DrugBank | DB00803 |
| UNII ID | Z67X93HJG1 (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
No data
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
423 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use